CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case–control study

Table 4 Joint effects of CYP17 polymorphisms and parity on risk of premenopausal breast cancer in Germany

CYP17 genotype	Cases, no. (%)	Controls, no. (%)	OR (95% CI)^a	OR (95% CI)^b
Parous women
A1/A1	139 (26.4)	253 (28.0)	1.00	1.00
A1/A2	189 (35.9)	330 (36.5)	1.03 (0.78–1.36)	1.05 (0.79–1.39)
A2/A2	75 (14.2)	122 (13.5)	1.12 (0.79–1.60)	1.16 (0.80–1.66)
Nulliparous women
A1/A1	41 (7.8)	70 (7.7)	1.04 (0.67–1.61)	1.01 (0.62–1.67)
A1/A2	55 (10.4)	94 (10.4)	1.04 (0.70–1.56)	1.05 (0.66–1.67)
A2/A2	28 (5.3)	35 (3.9)	1.43 (0.83–2.46)	1.48 (0.82–2.70)

^aAge-adjusted odds ratio (OR) and 95% confidence interval (CI). ^bMultivariate adjusted OR and 95% CI. Adjusted for age at menarche in years (≤ 12, 13 to 14, 15+); oral contraceptive use (no, yes); total months of breastfeeding (0, 1 to 12, >12); alcohol consumption (0, 1 to 18, >18 g/day); current body mass index as continuous variable; educational level (low, middle, high).

ISSN: 1465-542X